Skip to main content
. 2024 Mar 15;16(3):916–924. doi: 10.62347/NDGV1857

Table 4.

Treatment of thymalfasin-treated and non-thymalfasin-treated groups

SARS-CoV-2 nucleic acid negative conversion time (days) SARS-CoV-2 IgG antibody level when SARS-CoV-2 nucleic acid turned negative
Thymalfasin-treated group (n=24) 18.42±5.06 64.52±53.38
Non-thymalfasin-treated group (n=27) 19.07±6.43 73.26±51.69
t 0.398 0.583
P 0.693 0.563